US 7,517,523 B2
	Anti-MIF antibodies
Richard Bucala, Cos Cob, Conn. (US); Robert A. Mitchell, New York, N.Y. (US); Jurgen Bernhagen, New York, N.Y. (US); Thierry F. Calandra, New York, N.Y. (US); and Anthony Cerami, Shelter Island, N.Y. (US)
Assigned to Cytokine PharmaSciences, Inc., King of Prussia, Pa. (US)
Filed on Jun. 17, 2003, as Appl. No. 10/462,751.
Application 08/471705 is a division of application No. 08/462350, filed on Jun. 05, 1995, abandoned.
Application 10/462751 is a continuation of application No. 08/471705, filed on Jun. 06, 1995, granted, now 6,645,493.
Application 08/462350 is a continuation in part of application No. 08/243342, filed on May 16, 1994, abandoned.
Application 08/243342 is a continuation in part of application No. 08/063399, filed on May 17, 1993, abandoned.
Prior Publication US 2004/0053843 A1, Mar. 18, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C12P 21/00 (2006.01)

U.S. Cl. 424—130.1  [424/133.1; 424/141.1; 424/145.1; 424/158.1; 530/387.1; 530/387.3; 530/387.9; 530/388.1; 530/388.15; 530/389.1]

17 Claims

1. An isolated or purified anti-Macrophage Migration Inhibitory Factor (MIF) antibody, wherein the MIF has a molecular weight of approximately 12.5 kDa as determined by SDS PAGE, and wherein the anti-MIF antibody binds to and neutralizes a biological activity of the 12.5 kDa MIF selected from the group consisting of endotoxin lethality, cytokine-mediated toxicity, TNF-α lethality, septic shock, nitric oxide production by a macrophage, an immune response to malaria infection, an inflammatory immune response, induction of parasite killing by macrophages, and delayed type hypersensitivity response.